Clinical Significance of Genetic Markers in Colon Cancer
N/A
N/A
Both
Colorectal Cancer
Trial Information
Clinical Significance of Genetic Markers in Colon Cancer
OBJECTIVES:
- Determine the clinical and pathologic significance of unstable DNA elements in
colorectal cancer (tumor microsatellite instability).
- Determine the clinical and pathologic significance of loss of heterozygosity for
chromosomes 5, 8, 17, and 18 (as the primary targets) and of chromosomes 1, 14, and 22
(as the secondary targets) in colorectal cancer.
OUTLINE: DNA is examined for unstable elements (microsatellite instability and loss of
heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate
chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four
chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22).
Immunohistochemistry is used to test for the presence or absence of the genes involved in
DNA mismatch repair (hMLH1 and hMSH2).
Patients do not receive the results of the genetic testing and the results do not influence
the type or duration of treatment.
PROJECTED ACCRUAL: This study will accrue up to 708 specimens.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Must have had a resectable adenocarcinoma of the colon or rectum and must have
participated in one of the following NCCTG randomized clinical trials:
- 784852: No Treatment Control Versus Levamisole Versus Levamisole Plus
Fluorouracil (5-FU)
- 794604: No Treatment Control Versus 5-FU by Portal Vein Infusion
- 794751: Postoperative Radiation Versus Postoperative Radiation Plus Sequential
Chemotherapy with Methyl CCNU and 5-FU
- 844652: An Intergroup Study - An Evaluation of Levamisole Plus 5-FU as Surgical
Adjuvant Treatment for Resectable Adenocarcinoma of the Colon
- 864751: Phase III Protocol for Surgical Adjuvant Therapy of Rectal Carcinoma: A
Controller Evaluation of (A) Protracted-Infusion 5-FU as a Radiation Enhancer
and (B) 5-FU Plus Methyl-CCNU Chemotherapy
- 874651: M/N - A Controller Evaluation of Recombinant Interferon-gamma (IFL GM)
and 5-FU and Folinic Acid With or Without Levamisole as Adjuvant Treatment for
Resectable Adenocarcinoma of the Colon
- 894651: A Controller Phase III Evaluation of 5-FU Combined With Levamisole and
Leucovorin as Adjuvant Treatment for Resectable Colon Cancer
- Tissue blocks from the primary colorectal cancer must have been received by the NCCTG
operations office
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Type of Study:
Observational
Study Design:
N/A
Principal Investigator
Steven R. Alberts, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Mayo Clinic
Authority:
United States: Federal Government
Study ID:
CDR0000065549
NCT ID:
NCT00014079
Start Date:
September 1997
Completion Date:
Related Keywords:
- Colorectal Cancer
- colon cancer
- rectal cancer
- Colonic Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|---|
| Mayo Clinic - Jacksonville | Jacksonville, Florida 32224 |
| Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
| CCOP - Mayo Clinic Scottsdale Oncology Program | Scottsdale, Arizona 85259 |
